Maximum quantity allowed is 999
请选择数量
CAS RN: 877399-00-3 | 产品编码: B5682
(R)-5-Bromo-3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-2-amine
×
![]()
×
![(R)-5-Bromo-3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-2-amine](/_ui/responsive/theme-tci/images/missing_product_zoom.jpg "(R)-5-Bromo-3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-2-amine")
| 产品编码 | B5682 |
| 纯度/分析方法 | >98.0%(HPLC) |
| 分子式/分子量 | C__1__3H__1__0BrCl__2FN__2O = 380.04 |
| 外观与形状（20°C） | 固体 |
| 储存温度 | 室温 (15°C以下阴凉干燥处) |
| 包装和容器 | 1G-Glass Bottle with Plastic Insert （查看图片） |
| CAS RN | 877399-00-3 |
| Reaxys-RN | 12134679 |
| PubChem物质ID | 354335323 |
| MDL编号 | MFCD18207061 |
技术规格
| Appearance | White to Light yellow to Light orange powder to crystal |
| Specific rotation(value) | -64.0 to -70.0 deg(C=1, CHCL3) |
| Purity(HPLC) | min. 98.0 area% |
| Purity(with Total Nitrogen) | min. 98.0 % |
| Melting point | 108.0 to 113.0 °C |
物性（参考值）
| 熔点 | 109 °C |
| 比旋光度 [α]D | -67° (C=1,CHCl3) |
GHS
| 象形图 |
|
| 信号词 | Warning |
| 危险性说明 | H315 : Causes skin irritation. H319 : Causes serious eye irritation. |
| 防范说明 | P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ eye protection/ face protection. P302 + P352 : IF ON SKIN: Wash with plenty of water. P337 + P313 : If eye irritation persists: Get medical advice/ attention. P305 + P351 + P338 : IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P362 + P364 : Take off contaminated clothing and wash it before reuse. P332 + P313 : If skin irritation occurs: Get medical advice/ attention. |
相关法规
运输信息
| HS编码* | 2933.39-000 |
应用
A Synthetic Intermediate of Tyrosine Kinase Inhibitors
This product has been used as a synthetic intermediate of tyrosine kinase inhibitors, such as crizotinib (PF-02341066).
References
- Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
- Fit-for-Purpose Development of the Enabling Route to Crizotinib (PF-02341066)
- Synthesis of a Crizotinib Intermediate via Highly Efficient Catalytic Hydrogenation in Continuous Flow
应用
A Key Synthetic Intermediate of Crizotinib
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
References
- Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
- Fit-for-Purpose Development of the Enabling Route to Crizotinib (PF-02341066)
参考文献